TO THE EDITOR
Studies of familial acute myeloblastic leukaemia (AML) have identified RUNX1 (AML1, CBFA2) on chromosome 21 as the first familial AML susceptibility gene. 1, 2 Germline mutations in RUNX1 cause familial platelet disorder (FPD; MIM 601399), a rare autosomal-dominant disease characterized by qualitative and quantitative platelet defects and predisposition to the development of myeloid malignancies, in particular AML. 2 In addition to RUNX1, linkage analysis has implicated chromosome 16q21-23.2 as a familial AML predisposition locus. 3 Families segregating multiple cases of AML are rare. In 1998, we reported a family in which four members had documented evidence of developing AML. 4 Here, we provide strong evidence for an additional susceptibility locus for AML to 21q22.12 and 16q21-23.2 from a molecular analysis of this family.
All members of the family ( Figure 1 ) are white Caucasians and there is no evidence of consanguinity. We have previously excluded involvement of Fanconi and mutations in TP53. 4 Individual I:1 presented at the age of 34 years with AML. Individual II:2 presented at the age of 25 years with AML M4 with eosinophilia, cytogenetic analysis revealing an abnormal clone 46XY,del(6)(q21) in 5/16 cells. Individual II.4 presented at the age of 24 years with AML M1. No clonal cytogenetic abnormality was detected. Individual III:1 presented at the age of 4 years with AML M1. Cytogenetic analysis of individual III:1 at presentation was normal, but on relapse, the clonal abnormality 47,XY, þ 8 was observed, with clonal evolution to 47,XY, þ 8, þ 21 at subsequent relapse. Individuals II:2 and III:1 remain well 18 and 14 years from original diagnosis of AML, respectively, despite experiencing one or more relapses. Individual II:3 remains well in first remission 11 years from original diagnosis of AML. He has been shown to have a normal 46,XY karyotype. It is of interest that the clinical course of the AML in this family has shown good overall survival, despite multiple relapses in two members.
Germline samples from individuals I:2, II:2, II:3, II:4 and III:1 and tumour samples from II:2 and II:4 ( Figure 1 ) were obtained with informed consent and ethical review board approval in accordance with the tenets of the Declaration of Helsinki. In all, 15 microsatellite markers, D21S120, D21S1899, D21S368, D21S1280, D21S217, D21S263, D21S1413, D21S370, D21S65, D21S1921, D21S1255, D21S167, D21S1899, D21S1574, and D21S1575 were used to generate genotypes surrounding RUNX1 on chromosome 21q22 (Figure 1 ). These were used to construct haplotypes around the 21q22.12 region in order to determine segregation in the family. A similar analysis was undertaken on chromosome 16, using seven microsatellite markers, D16S265, D16S186, D16S398, D16S301, D16S2793, D16S518, and D16S684 (Figure 2) . Fluorescent-labelled amplified products were separated on an ABI Prism 3100 genetic analyzer with allele sizes determined by use of the ABI PRISM s Genotyper software package (Applied Biosystems, Foster City, CA, USA).
Linkage of AML in the family to chromosome 16 ( Figure 1 ) could be excluded on the basis of nonhaplotype sharing among affected family members. Chromosome 21 haplotype marker data ( Figure 2) did not preclude linkage. Mutations detected in FPD have been identified within the functional region of RUNX1 defined by the Runt domain, which is encoded by exons 3, 4, 5, and 6.
1,2,5 While the clinical phenotype of the family is not compatible with a diagnosis of classical FPD, it is conceivable that allelic variants of RUNX1 outside those defining the Runt domain might confer susceptibility and be associated with a different phenotype. To mitigate against this possibility we screened the 5 0 UTR and the entire gene by sequencing all exons and intronic-exonic boundaries using PCR primers designed by Primer 3 software (http://www.broad.mit. edu/cgi-bin/primer/primer3_www.cgi; all primer sequences and PCR conditions are available upon request). Amplified PCR Figure 1 Pedigree showing the autosomal-dominant inheritance of AML in the family with associated chromosome 16 haplotypes. Blackened symbols denote affected individuals and stars indicate the individuals from whom tumour samples were available for genotyping. products were purified (Qiagen Inc., Valencia, CA, USA) and bidirectionally sequenced using BigDye Terminator chemistry implemented on an ABI Prism 3100 sequencer. Sequences were aligned and compared to consensus sequences obtained from the human genome databases (http://genome.ucsc.edu, May 2004 release; http://www.ncbi.nlm.nih.gov) using the software package Sequencer (Version 3.1.1; Gene Codes Corp., Ann Arbor, MI, USA).
No missense, truncating mutations or sequence changes likely to disrupt splice sites were identified in RUNX1. In addition, no pathogenic mutations were detected in presentation tumour samples obtained from individuals II:2 and II:4. The possibility of a large-scale deletion of RUNX1 segregating in the family is excluded by the finding of a novel C/A base change located at þ 27 in the 3'UTR of RUNX1 (Figure 2) . The 3'UTR SNP which displayed Mendelian inheritance within the family, was present in the heterozygous state in the tumour sample from individual II:4, suggesting that both copies of RUNX1 were still present in the somatic tissue.
The involvement of a gene on chromosome 16q21-23.2 in the aetiology of familial AML derives from the observation of linkage in a large family segregating the disease. 3 The genetic basis of the linkage is unknown. The possibility that the linkage in the family is the consequence of a mutation in CBFB whose product CBFb interacts with RUNX1 has recently been excluded. 6 As we were able to demonstrate nonsegregation of chromosome 16q21-23.2 markers with disease in our family, the results indicate that there is at least one additional familial AML predisposition locus.
Figure 2
Chromosome 21 haplotypes including the relative position of the novel 3'UTR RUNX1 SNP in the family. Blackened symbols denote affected individuals and stars indicate the individuals from whom tumour samples were available for genotyping and RUNX1 sequencing.
